XJPX4524
Market cap54mUSD
Jan 17, Last price
2,085.00JPY
1D
0.00%
1Q
-2.16%
Jan 2017
-24.04%
Name
Morishita Jintan Co Ltd
Chart & Performance
P/E
12.21
P/S
0.69
EPS
170.74
Div Yield, %
2.40%
Shrs. gr., 5y
—
Rev. gr., 5y
-0.07%
Revenues
12.41b
+9.22%
Net income
697m
+41.96%
CFO
196m
-83.38%
Dividend
Mar 28, 20250 JPY/sh
Profile
Morishita Jintan Co., Ltd. produces and distributes pharmaceuticals, quasi drugs, medical devices, and food products in Japan. It operates through Healthcare Business and Capsule Business divisions. The Healthcare Business division manufactures and sells Jintan branded products, as well as engages in OEM of dietary supplements, cosmetics, foods, etc. The Capsule Business division is involved in the OEM/ODM of pharmaceuticals, foods, etc., as well as the development of industrial use capsules. Morishita Jintan Co., Ltd. was founded in 1893 and is headquartered in Osaka, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | |
| Income | |||||
Revenues | 12,406,000 9.22% | 11,359,000 18.78% | 9,563,000 1.44% | ||
Cost of revenue | 11,494,000 | 8,501,000 | 7,081,000 | ||
Unusual Expense (Income) | |||||
NOPBT | 912,000 | 2,858,000 | 2,482,000 | ||
NOPBT Margin | 7.35% | 25.16% | 25.95% | ||
Operating Taxes | 123,000 | 131,000 | 101,000 | ||
Tax Rate | 13.49% | 4.58% | 4.07% | ||
NOPAT | 789,000 | 2,727,000 | 2,381,000 | ||
Net income | 697,000 41.96% | 491,000 73.50% | 283,000 37.38% | ||
Dividends | (163,000) | (152,000) | (152,000) | ||
Dividend yield | 1.64% | 1.86% | 1.98% | ||
Proceeds from repurchase of equity | |||||
BB yield | |||||
| Debt | |||||
Debt current | 319,000 | 295,000 | 317,000 | ||
Long-term debt | 106,000 | 242,000 | 469,000 | ||
Deferred revenue | 658,000 | 644,000 | |||
Other long-term liabilities | 780,000 | 23,000 | 24,000 | ||
Net debt | (5,059,000) | (5,956,000) | (4,583,000) | ||
| Cash flow | |||||
Cash from operating activities | 196,000 | 1,179,000 | 543,000 | ||
CAPEX | (608,000) | (464,000) | (702,000) | ||
Cash from investing activities | (1,152,000) | (474,000) | (463,000) | ||
Cash from financing activities | (362,000) | (433,000) | (645,000) | ||
FCF | (1,192,000) | 2,834,000 | 2,218,000 | ||
| Balance | |||||
Cash | 1,092,000 | 2,409,000 | 2,138,000 | ||
Long term investments | 4,392,000 | 4,084,000 | 3,231,000 | ||
Excess cash | 4,863,700 | 5,925,050 | 4,890,850 | ||
Stockholders' equity | 11,282,000 | 10,537,000 | 9,608,000 | ||
Invested Capital | 8,484,300 | 6,517,950 | 6,945,150 | ||
ROIC | 10.52% | 40.51% | 34.56% | ||
ROCE | 6.39% | 21.31% | 19.71% | ||
| EV | |||||
Common stock shares outstanding | 4,084 | 4,081 | 4,077 | ||
Price | 2,440.00 22.00% | 2,000.00 6.04% | 1,886.00 -6.03% | ||
Market cap | 9,964,958 22.09% | 8,162,310 6.15% | 7,689,222 -5.94% | ||
EV | 4,905,958 | 2,206,310 | 3,106,222 | ||
EBITDA | 1,488,000 | 3,485,000 | 3,067,000 | ||
EV/EBITDA | 3.30 | 0.63 | 1.01 | ||
Interest | 2,000 | 2,000 | 7,000 | ||
Interest/NOPBT | 0.22% | 0.07% | 0.28% | ||